IMFINZI® (durvalumab) is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
There are no contraindications for IMFINZI.
IMFINZI can cause immune-mediated adverse reactions, including immune-mediated pneumonitis, hepatitis, colitis or diarrhea, endocrinopathies (including thyroid disorders, adrenal insufficiency, type 1 diabetes, and hypophysitis), nephritis, dermatologic reactions, and other immune-mediated adverse reactions; infection; and infusion-related reactions. Please refer to the full Prescribing Information for important dosage modification and management information specific to adverse reactions.
Serious, potentially fatal risks were seen with IMFINZI. Serious adverse reactions occurred in 29% of patients with unresectable Stage III NSCLC receiving IMFINZI (n=475). The most frequent serious adverse reactions (≥2% of patients) were pneumonitis or radiation pneumonitis (7%) and pneumonia (6%). The most common adverse reactions with IMFINZI (≥20%) were cough (40%), fatigue (34%), pneumonitis or radiation pneumonitis (34%), upper respiratory tract infections (26%), dyspnea (25%), and rash (23%). Advise women not to become pregnant or breastfeed during treatment with IMFINZI and for at least 3 months after the last dose. The safety and effectiveness of IMFINZI have not been established in pediatric patients.
Please see complete Prescribing Information, including Medication Guide.
You may report side effects related to AstraZeneca products by clicking here.